Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40KHL | ISIN: US64113L2025 | Ticker-Symbol:
NASDAQ
05.06.25 | 19:25
2,480 US-Dollar
0,00 % 0,000
1-Jahres-Chart
NETCAPITAL INC Chart 1 Jahr
5-Tage-Chart
NETCAPITAL INC 5-Tage-Chart

Aktueller Chart NETCAPITAL Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
NETCAPITAL INC-Investoren interessieren sich auch für diese Wertpapiere
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy ChainBOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc.LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93. Sonoma...
► Artikel lesen
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory AgencyBOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
Jaguar Health, Inc.: Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight SeriesClick here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate...
► Artikel lesen
Jaguar Health, Inc.: Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and...
► Artikel lesen
Jaguar Health, Inc.: First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion DiseaseAs announced, initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient...
► Artikel lesen
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business UpdatesWARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company...
► Artikel lesen
Windtree Therapeutics Regains Compliance with Nasdaq Listing RulesWARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech...
► Artikel lesen
Windtree Therapeutics: Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart FailureWARRINGTON, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative...
► Artikel lesen